The estimated Net Worth of Barbara K Finck is at least $51.6 Tysiąc dollars as of 10 September 2018. Dr Finck owns over 1,760 units of Coherus Biosciences Inc stock worth over $51,608 and over the last 10 years he sold CHRS stock worth over $0.
Dr has made over 4 trades of the Coherus Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,760 units of CHRS stock worth $2,499 on 10 September 2018.
The largest trade he's ever made was exercising 1,760 units of Coherus Biosciences Inc stock on 10 September 2018 worth over $2,499. On average, Dr trades about 640 units every 8 days since 2014. As of 10 September 2018 he still owns at least 38,803 units of Coherus Biosciences Inc stock.
You can see the complete history of Dr Finck stock trades at the bottom of the page.
Dr. Barbara K. Finck M.D. is the Acting Chief Medical Officer at Coherus Biosciences Inc.
Dr D is 74, he's been the Acting Chief Medical Officer of Coherus Biosciences Inc since . There are no older and 15 younger executives at Coherus Biosciences Inc.
Barbara's mailing address filed with the SEC is 333 Twin Dolphin Dr #600, Redwood City, CA 94065, USA.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle oraz James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: